We report a case of a fetus with shortened proximal long bones, ambiguous genitalia, intrauterine growth restriction and abnormal umbilical artery Doppler velocities observed on antenatal ultrasound exam. At 34 weeks the patient revealed methotrexate/misoprostol exposure at 6 weeks gestational age in attempted medical termination of pregnancy. On newborn exam, the baby had dysmorphic facial features, a short torso, scoliosis, a micropenis (phallus <1 cm) and shortened proximal long bones both upper and lower extremities. X-ray exam revealed a hemivertebra at T10 level, rib abnormalities, shortened proximal long bones, an absent pubic bone and bilateral knee ossification centers. With methotrexate exposure, improved counseling and surveillance could potentially avoid these significant abnormalities and prevent psychological distress.
Introduction
Methotrexate, a folate antagonist which reversibly inhibits the enzyme dihydrofolate reductase, limits the availability of one-carbon fragments necessary for the synthesis of purines which interferes with the conversion of deoxyuridylate to thymidylate in the synthesis of DNA and cell reproduction. 1 Methotrexate is commonly used in reproductive aged females for the management of medical conditions including autoimmune disorders (juvenile rheumatoid arthritis, systemic lupus erythematosus), dermatologic conditions (psoriasis) and malignancies (leukemia, lymphoma and gestational trophoblastic disease). Methotrexate is also used in the medical management of ectopic pregnancy and for medical termination of pregnancy. Normal pregnancy outcome has been reported following exposure to methotrexate; however, first trimester exposure has been associated with multiple malformations. 1 We present a case of failed first trimester medical termination of pregnancy with exposure to methotrexate followed by misoprostol with continuation of the gestation that resulted in intrauterine growth restriction, multiple skeletal deformities and a micropenis.
Case EB was a 23-year-old prima gravid Hispanic female with an LMP 06 December 2004 and an EDC 13 September 2005. She presented for prenatal care at 25 weeks with an unremarkable medical or surgical history and she did not smoke or use drugs/alcohol. Initial physical exam was notable for a uterine size smaller then expected, measuring 23 cm. She was referred to our ultrasound unit at 31 weeks gestation and the significant findings on exam included: shortened proximal long bones, ambiguous genitalia and an increased umbilical artery S/D ratio of 4.1. Overall biometric measurements estimated the fetal weight at 1440 g (29% for gestational age). The mean humeral measurements were 45.2 mm (26 weeks, 5 days) and femoral length measurements 53.5 mm (28 weeks, 2 days) without bowing. A 3-week follow-up sonographic exam showed limited fetal growth, with an estimated fetal weight of 1728 g (9% for gestational age) with umbilical artery S/D remaining 4.1 and normal amniotic fluid volume. The mean humeral measurements were 50.9 mm (29 weeks, 1 day) and femoral length measurements 57.2 mm (30 weeks, 0 days). At 34 weeks the patient disclosed use of methotrexate at 6 weeks gestational age for medical termination of pregnancy in the Dominican Republic. She had taken oral methotrexate 10 mg daily for 10 days followed by diclofenac/misoprostol 50 mg/200 mcg orally for 4 days with no bleeding or follow-up. Serial antepartum testing remained reassuring and at 39 weeks, labor induction was initiated secondary to the fetal growth restriction. Repetitive late decelerations and a minimally dilated cervix resulted in cesarean delivery of a 2370 g male baby with Apgar scores of 9 at 1 min and 9 at 5 min. The umbilical cord arterial pH was 7.23 with a base excess of À2.4.
On newborn exam, notable dysmorphic facial features including an open large flattened anterior fontanelle, hypertelorism, a broad nasal bridge, mild micrognathia and a normally shaped skull with a head circumference of 34 cm. Exam of the body revealed a short torso, scoliosis, a micropenis (phallus <1 cm) with a normal scrotum and descended testes, shortened proximal long bones of both upper and lower extremities, bilateral fifth finger clinodactyly and bilateral second toe clinodactyly. X-ray examinations of the chest and extremities established a hemivertebra at T10 level resulting in mild scoliosis, 10 ribs on the left, nine ribs on the right, minimally shortened proximal long bones, absent pubic bone and bilaterally absent knee ossification centers. (Figure 1a, b) Hormonal workup, auditory testing and New York newborn screening were normal and chromosome analysis revealed a 46 XY pattern.
The patient stated that did not wish to disclose the use of methotrexate to avoid judgment. The father of the baby was also unaware of the events of early pregnancy. The patient expressed significant guilt related to the newborn abnormalities and she was referred for counseling. After social services intervention, the baby was discharged home on day of life 10 with outpatient follow-up scheduled.
Discussion
Our newborn expressed many of the findings associated with first trimester methotrexate exposure with several findings noted on antenatal ultrasound exam. The constellation of teratogenic effects, the fetal aminopterin/methotrexate syndrome, consists of skull, limb and facial abnormalities along with growth deficiency. Skull defects include absence or hypoplasia of the frontal bones, deficient ossification of bones, absence of sutures and large fontanelles.
Dysmorphic facial features include hypertelorism, prominent eyes secondary to hypoplastic supraorbital ridges, short palpebral fissures, a wide nasal bridge, small, malformed or low set ears and micrognathia. Skeletal anomalies include oligodactyly, syndactyly, mesomelia, dislocated hips, clubfeet and rib abnormalities. Other reported features include cleft palate, neural tube defects and congenital heart defects. [2] [3] [4] Our case is first to describe abnormal genitalia diagnosed antenatally with ultrasound. Addar 5 reported methotrexate exposure for a presumed ectopic gestation without abnormalities on ultrasound exam and a newborn male with a bifid scrotum, micropenis, hypospadias and a hemivertebra with scoliosis.
Misoprostol, a prostaglandin E1 analogue, is an abortofacient alone or in combination with methotrexate. Failed pregnancy termination and teratogenic effects have also been associated with misoprostol, most commonly Möbius' syndrome (congenital facial paralysis), limb reduction defects, abdominal wall defects and arthrogryposis. These effects are thought to be secondary to vascular disruption due to uterine contraction during the first trimester. 6, 7 Secondary to the frequent combination of methotrexate with misoprostol in medical termination of pregnancy it is difficult to completely isolate the teratogenic effects of the two medications. While the anomalies we report can be explained solely on the basis of methotrexate exposure, it is possible these medications act in conjunction to produce the syndrome we described.
Our patient unknowingly continued her pregnancy, returned home and was beyond legal limits for termination in New York. She concealed her usage of methotrexate to both the father of the baby and her healthcare providers. The expected malformation rate after in utero exposure to methotrexate exposure is not known. 8 Methotrexate, when used alone for termination of pregnancy, can fail to complete the abortion over a 3-week period in 25% of women; however, with the addition of misoprostol, a 2-10% failure rate has been reported. 9, 10 Despite frequent usage of single low-dose methotrexate and misoprostol in termination of pregnancy, both physician and patient knowledge related to potential teratogenic effects remains inadequate. 11 Patients should be counseled and made aware of the potential teratogenic effects before the use of these medications with the most critical period for development of embryopathy being the eighth through the 10th weeks of gestation. 8, 12 We, as providers, must obtain assurance that pregnancy is undesired and must insist on close follow-up to document successful medical termination of an intrauterine pregnancy or medical treatment of an ectopic pregnancy. There are growing concerns related to RU-486 and maternal deaths which may lead to increase usage of methotrexate for termination in the US and worldwide. 13 We hope improved counseling and surveillance can avoid future infants being affected by significant abnormalities such as those seen in our newborn, and also prevent mothers suffering from the psychological distress seen in our patient. 
